Abelacimab: A leap forward in anticoagulation with FXI and FXIa Inhibition

• Main Authors: Hisham A. Badreldin (Author), Nada Alsuhebany (Author), Mohammed Alzahrani (Author), Abdulmajeed M. Alshehri (Author), Maha Aldoughaim (Author), Saleh Alqifari (Author), Omar Yassin (Author), Lama Alfehaid (Author), Tariq Alqahtani (Author)
• Format: Book
• Published: Elsevier, 2024-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Direct Oral Anticoagulants (DOACs) have revolutionized the treatment of thromboembolic disorders, offering targeted, effective, and safer alternatives to traditional anticoagulants like heparins and vitamin K antagonists (VKAs). Despite their benefits, DOACs have drawbacks, including an increased ri...